You are in: Home > Articles > 27th May 2007 > Recommendations for patients using Butrans (Transdermal Burenorphine) patch for the management of chronic non-malignant pain who experience erythematous (red) rash/ skin irritation at the site of the patch.
27th May 2007 at 16:31 BST by Dr C.A.Jenner MB BS, FRCA. Permalink.
Recommendations for patients using Butrans (Transdermal Burenorphine) patch for the management of chronic non-malignant pain who experience erythematous (red) rash/ skin irritation at the site of the patch.
Up to 10% of patients who use the Butrans (Transdermal Burenorphine patch) can suffer with local skin irritability, manifest as itching, redness or blistering of the skin- despite the fact that they benefit from using the patch.
Anecdotally many physicians have found the following steps to be of benefit in those patients who find the patches to be helpful, but suffer with skin irritation
‘Recommendations for patients using Butrans (Transdermal Burenorphine) patch for the management of chronic non-malignant pain who experience erythematous (red) rash/ skin irritation at the site of the patch.’ was posted by Dr C.A.Jenner MB BS, FRCA on 27th May 2007 at 16:31 BST and filed under medication.
Subscribe to RSS for Articles . What is RSS?
© London Pain Consultants 2006. Telephone: 0845 045 0250.